These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 35298079)

  • 1. Improving the Model for End-Stage Liver Disease with sodium by incorporating kidney dysfunction types.
    Cullaro G; Verna EC; McCulloch CE; Lai JC
    Hepatology; 2022 Sep; 76(3):689-699. PubMed ID: 35298079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Association Between Renal Function Pattern and Mortality in Patients With Cirrhosis.
    Cullaro G; Verna EC; Lai JC
    Clin Gastroenterol Hepatol; 2019 Oct; 17(11):2364-2370. PubMed ID: 30716479
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Addition of C-Reactive Protein and von Willebrand Factor to Model for End-Stage Liver Disease-Sodium Improves Prediction of Waitlist Mortality.
    Starlinger P; Ahn JC; Mullan A; Gyoeri GP; Pereyra D; Alva-Ruiz R; Hackl H; Reiberger T; Trauner M; Santol J; Simbrunner B; Mandorfer M; Berlakovich G; Kamath PS; Heimbach J
    Hepatology; 2021 Sep; 74(3):1533-1545. PubMed ID: 33786862
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Validating a novel score based on interaction between ACLF grade and MELD score to predict waitlist mortality.
    Abdallah MA; Kuo YF; Asrani S; Wong RJ; Ahmed A; Kwo P; Terrault N; Kamath PS; Jalan R; Singal AK
    J Hepatol; 2021 Jun; 74(6):1355-1361. PubMed ID: 33326814
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development and validation of the Gender-Equity Model for Liver Allocation (GEMA) to prioritise candidates for liver transplantation: a cohort study.
    Rodríguez-Perálvarez ML; Gómez-Orellana AM; Majumdar A; Bailey M; McCaughan GW; Gow P; Guerrero M; Taylor R; Guijo-Rubio D; Hervás-Martínez C; Tsochatzis EA
    Lancet Gastroenterol Hepatol; 2023 Mar; 8(3):242-252. PubMed ID: 36528041
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of the Model for End-stage Liver Disease sodium (MELD-Na) score in the Eurotransplant region.
    Goudsmit BFJ; Putter H; Tushuizen ME; de Boer J; Vogelaar S; Alwayn IPJ; van Hoek B; Braat AE
    Am J Transplant; 2021 Jan; 21(1):229-240. PubMed ID: 32529758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MELD-Na Accurately Predicts 6-Month Mortality in Patients With Decompensated Cirrhosis: Potential Trigger for Hospice Referral.
    Brown C; Aksan N; Muir AJ
    J Clin Gastroenterol; 2022 Nov-Dec 01; 56(10):902-907. PubMed ID: 34802021
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Region 11 MELD Na exception prospective study.
    Fisher RA; Heuman DM; Harper AM; Behnke MK; Smith AD; Russo MW; Zacks S; McGillicuddy JW; Eason J; Porayko MK; Northup P; Marvin MR; Hundley J; Nair S
    Ann Hepatol; 2012; 11(1):62-7. PubMed ID: 22166562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Allocating Livers for Transplantation Based on Model for End-Stage Liver Disease-Sodium Scores on Patient Outcomes.
    Nagai S; Chau LC; Schilke RE; Safwan M; Rizzari M; Collins K; Yoshida A; Abouljoud MS; Moonka D
    Gastroenterology; 2018 Nov; 155(5):1451-1462.e3. PubMed ID: 30056096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Moderate ascites identifies patients with low model for end-stage liver disease scores awaiting liver transplantation who have a high mortality risk.
    Somsouk M; Kornfield R; Vittinghoff E; Inadomi JM; Biggins SW
    Liver Transpl; 2011 Feb; 17(2):129-36. PubMed ID: 21280185
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model for end-stage liver disease-sodium underestimates 90-day mortality risk in patients with acute-on-chronic liver failure.
    Hernaez R; Liu Y; Kramer JR; Rana A; El-Serag HB; Kanwal F
    J Hepatol; 2020 Dec; 73(6):1425-1433. PubMed ID: 32531416
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Addition of Kidney Dysfunction Type to MELD-Na for the Prediction of Survival in Cirrhotic Patients Awaiting Liver Transplantation in Comparison with MELD 3.0 with Albumin.
    Yeom KM; Chang JI; Yoo JJ; Moon JE; Sinn DH; Kim YS; Kim SG
    Diagnostics (Basel); 2023 Dec; 14(1):. PubMed ID: 38201348
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The von Willebrand Factor Facilitates Model for End-Stage Liver Disease-Independent Risk Stratification on the Waiting List for Liver Transplantation.
    Györi GP; Pereyra D; Rumpf B; Hackl H; Köditz C; Ortmayr G; Reiberger T; Trauner M; Berlakovich GA; Starlinger P
    Hepatology; 2020 Aug; 72(2):584-594. PubMed ID: 31773739
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Natural history of NASH cirrhosis in liver transplant waitlist registrants.
    Lim WH; Ng CH; Tan D; Tseng M; Xiao J; Yong JN; Zeng RW; Cho E; Tay P; Ang CZ; Koh JH; Teng M; Syn N; Kow A; Huang DQ; Tan EX; Rinella ME; Sanyal A; Muthiah M; Siddiqui MS
    J Hepatol; 2023 Oct; 79(4):1015-1024. PubMed ID: 37307997
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reduced Access to Liver Transplantation in Women: Role of Height, MELD Exception Scores, and Renal Function Underestimation.
    Allen AM; Heimbach JK; Larson JJ; Mara KC; Kim WR; Kamath PS; Therneau TM
    Transplantation; 2018 Oct; 102(10):1710-1716. PubMed ID: 29620614
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MELD-GRAIL-Na: Glomerular Filtration Rate and Mortality on Liver-Transplant Waiting List.
    Asrani SK; Jennings LW; Kim WR; Kamath PS; Levitsky J; Nadim MK; Testa G; Leise MD; Trotter JF; Klintmalm G
    Hepatology; 2020 May; 71(5):1766-1774. PubMed ID: 31523825
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Model for End-Stage Liver Disease/Pediatric End-Stage Liver Disease exception policy and outcomes in pediatric patients with hepatopulmonary syndrome requiring liver transplantation.
    Raza MH; Kwon Y; Kobierski P; Misra AC; Lim A; Goldbeck C; Etesami K; Kohli R; Emamaullee J
    Liver Transpl; 2023 Feb; 29(2):134-144. PubMed ID: 35876731
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MELD 3.0: The Model for End-Stage Liver Disease Updated for the Modern Era.
    Kim WR; Mannalithara A; Heimbach JK; Kamath PS; Asrani SK; Biggins SW; Wood NL; Gentry SE; Kwong AJ
    Gastroenterology; 2021 Dec; 161(6):1887-1895.e4. PubMed ID: 34481845
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cystatin C and Sarcopenia Predict Acute on Chronic Liver Failure Development and Mortality in Patients on the Liver Transplant Waiting List.
    Mauro E; Crespo G; Martinez-Garmendia A; Gutierrez-Acevedo MN; Diaz JM; Saidman J; Bermudez C; Ortiz-Patron J; Garcia-Olveira L; Zalazar F; Narvaez A; Spina JC; Orta R; Savluk L; Piano S; Marciano S; Gadano A
    Transplantation; 2020 Jul; 104(7):e188-e198. PubMed ID: 32150034
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Superiority of the new sex-adjusted models to remove the female disadvantage restoring equity in liver transplant allocation.
    Marrone G; Giannelli V; Agnes S; Avolio AW; Baiocchi L; Berardi G; Ettorre GM; Ferri F; Corradini SG; Grieco A; Guglielmo N; Lenci I; Lionetti R; Mennini G; Milana M; Rossi M; Spoletini G; Tisone G; Manzia TM; Lai Q
    Liver Int; 2024 Jan; 44(1):103-112. PubMed ID: 37752798
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.